DexCom (NASDAQ:DXCM) Insider Kevin Sayer Sells 26,756 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) insider Kevin Sayer sold 26,756 shares of DexCom stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $72.00, for a total value of $1,926,432.00. Following the sale, the insider directly owned 355,726 shares in the company, valued at $25,612,272. The trade was a 7.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 1.6%

Shares of NASDAQ DXCM opened at $73.57 on Wednesday. The company has a 50 day simple moving average of $68.74 and a 200 day simple moving average of $68.28. The firm has a market cap of $28.39 billion, a PE ratio of 31.44, a price-to-earnings-growth ratio of 1.19 and a beta of 1.45. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $89.98. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.95 and a quick ratio of 1.64.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the company earned $0.32 EPS. The firm’s revenue was up 15.0% compared to the same quarter last year. On average, research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DXCM. Raymond James Financial restated a “strong-buy” rating and issued a $91.00 price objective on shares of DexCom in a report on Monday, June 8th. Sanford C. Bernstein set a $77.00 price target on DexCom in a research note on Friday, May 1st. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective on the stock in a research note on Tuesday, March 24th. Stifel Nicolaus set a $90.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, June 5th. Finally, Benchmark reissued a “buy” rating on shares of DexCom in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $84.88.

Institutional Investors Weigh In On DexCom

Large investors have recently added to or reduced their stakes in the business. Reflection Asset Management bought a new position in shares of DexCom during the 4th quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new position in shares of DexCom during the 1st quarter valued at $25,000. CVA Family Office LLC lifted its position in shares of DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares during the period. MCF Advisors LLC bought a new position in DexCom during the fourth quarter worth $32,000. Finally, ORG Partners LLC boosted its stake in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.